2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer

Breast cancer remains the most commonly diagnosed cancer among women worldwide, but it is not a single disease. Distinct molecular subtypes—defined by hormone receptor (HR) status, HER2 expression, and emerging genomic alterations such as ESR1

Continue Reading